GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » PB Ratio

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) PB Ratio : 0.00 (As of May. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Cannabis Bioscience International Holdings's share price is $0.00065. Cannabis Bioscience International Holdings's Book Value per Share for the fiscal year that ended in May. 2011 was $4.81. Hence, Cannabis Bioscience International Holdings's PB Ratio of today is 0.00.

The historical rank and industry rank for Cannabis Bioscience International Holdings's PB Ratio or its related term are showing as below:

During the past 5 years, Cannabis Bioscience International Holdings's highest PB Ratio was 0.02. The lowest was 0.01. And the median was 0.01.

CBIH's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.97
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Cannabis Bioscience International Holdings's average Book Value Per Share Growth Rate was -100.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 511.80% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannabis Bioscience International Holdings was 511.80% per year. The lowest was 511.80% per year. And the median was 511.80% per year.

Back to Basics: PB Ratio


Cannabis Bioscience International Holdings PB Ratio Historical Data

The historical data trend for Cannabis Bioscience International Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings PB Ratio Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11
PB Ratio
- - - 0.75 0.16

Cannabis Bioscience International Holdings Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 May09 Nov09 May10 Nov10 May11 Nov11 Nov22 Nov23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.16 0.05 - -

Competitive Comparison of Cannabis Bioscience International Holdings's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Bioscience International Holdings's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's PB Ratio falls into.



Cannabis Bioscience International Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cannabis Bioscience International Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (A: May. 2011)
=0.00065/4.808
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cannabis Bioscience International Holdings  (OTCPK:CBIH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cannabis Bioscience International Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.